FDA.reportPublic FDA data

AREPANRIX vaccine Injectable Suspension

RxCUI
2743209
RxNorm name
AREPANRIX vaccine Injectable Suspension
Display name
AREPANRIX vaccine Injectable Suspension
Full name
AREPANRIX vaccine Injectable Suspension
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:26

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125419ArepanrixInfluenza A [H5] Monovalent Vaccine, Adjuvanted351(a)Disc2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
ecf36ac9-9eb7-4008-8657-9bb6fb1bb28cAREPANRIX vaccine Injectable Suspension [PSN] · influenza A virus A/Astrakhan/3212/2020 (H5N8) antigen 0.0075 MG/ML Injectable Suspension [Arepanrix] [SBD] · Arepanrix 0.0075 MG/ML Injectable Suspension [SY] · Arepanrix vaccine Injectable Suspension [SY]41These highlights do not include all the information needed to use AREPANRIX safely and effectively. See full prescribing information for AREPANRIX. AREPANRIX (Influenza A [H5] Monovalent Vaccine, Adjuvanted) injectable emulsion, for intramuscular use Initial U.S. Approval: 201320260428